Gough G. Au - Concepedia

Author

Gough G. Au

Australian Centre for Disease Preparedness ORCID

Also Known As

G. Au, Gough Au, Gough G Au, Gough G. Au, Gough Geoffrey Au

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

Australian Centre for Disease Preparedness Commonwealth Scientific and Industrial Research Organisation University of Newcastle Australia University of York Peter Doherty Institute

About

Gough G. Au is an author at Australian Centre for Disease Preparedness specializing in medicine, immunology, and virology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	14	654
2	Cell Biology	5	5	189
3	Social Sciences	1	1	39
4	Epidemiology	1	1	160
5	Gastroenterology	1	1	24

Gough G. Au

Publications

1.2K

Citations

H-Index

Page 1

	Year	Citations
Altered microRNA expression in COVID-19 patients enables identification of SARS-CoV-2 infection Ryan J. Farr, Christina L. Rootes, Louise C. Rowntree, PLoS Pathogens Altered Microrna ExpressionViral DiagnosticsSars-cov-2 InfectionMedicineThree-mirna Signature	2021	160
Systemic Therapy of Malignant Human Melanoma Tumors by a Common Cold-Producing Enterovirus, Coxsackievirus A21 Darren R. Shafren, Gough G. Au, Tam Nguyen, Clinical Cancer Research	2004	154
Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer Nicola Annels, David Mansfield, Mehreen Arif, Clinical Cancer Research	2019	118
Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma Gough G. Au, Lisa F. Lincz, Arno Enno, British Journal of Haematology Oncolytic Coxsackievirus A21ImmunologyPathologyImmunotherapyTumor Biology	2007	96
Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21 Gough G. Au, Anders Lindberg, Richard D. Barry, International Journal of Oncology Cva21 Receptor ExpressionMedicineMelanomaImmunologyCancer Growth	2005	82
Experimental and in silico evidence suggests vaccines are unlikely to be affected by D614G mutation in SARS-CoV-2 spike protein Alexander J. McAuley, Michael J. Kuiper, Peter A. Durr, npj Vaccines VaccinationViral EvolutionVaccine DevelopmentSilico EvidenceVirus Neutralisation Assays	2020	72
Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus Nicola Annels, Mehreen Arif, Guy R. Simpson, Molecular Therapy — Oncolytics	2018	59
ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets Glenn A. Marsh, Alexander J. McAuley, Gough G. Au, npj Vaccines	2021	58
Cellular receptor interactions of C-cluster human group A coxsackieviruses Nicole G. Newcombe, Per Andersson, Emil Johansson, Journal of General Virology Unidentified Internalization ReceptorMolecular VirologyCellular Receptor InteractionsPathogenesisViral Pathogenesis	2003	48
Potent Oncolytic activity of human enteroviruses against human prostate cancer Linda J. Berry, Gough G. Au, Richard D. Barry, The Prostate	2008	44

Page 1